34.05
-0.69 (-1.99%)
| Penutupan Terdahulu | 34.74 |
| Buka | 34.39 |
| Jumlah Dagangan | 457,440 |
| Purata Dagangan (3B) | 901,733 |
| Modal Pasaran | 2,990,067,456 |
| Harga / Pendapatan (P/E Ke hadapan) | 4.65 |
| Harga / Jualan (P/S) | 14.02 |
| Harga / Buku (P/B) | 2.97 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 May 2026 |
| Margin Operasi (TTM) | -5,147.81% |
| EPS Cair (TTM) | -3.65 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 78.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.54% |
| Nisbah Semasa (MRQ) | 13.92 |
| Aliran Tunai Operasi (OCF TTM) | -264.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -164.58 M |
| Pulangan Atas Aset (ROA TTM) | -21.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | IDEAYA Biosciences, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.90 |
|
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.90% |
| % Dimiliki oleh Institusi | 117.09% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Federated Hermes, Inc. | 31 Dec 2025 | 3,395,771 |
| Logos Global Management Lp | 31 Dec 2025 | 3,125,000 |
| Fiera Capital Corp | 31 Dec 2025 | 2,437,262 |
| Deerfield Management Company, L.P. | 31 Dec 2025 | 2,153,043 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 65.00 (Citigroup, 90.90%) | Beli |
| Median | 51.00 (49.78%) | |
| Rendah | 49.00 (RBC Capital, 43.91%) | Beli |
| Purata | 54.33 (59.56%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 33.31 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 19 Feb 2026 | 65.00 (90.90%) | Beli | 32.90 |
| Guggenheim | 18 Feb 2026 | 50.00 (46.84%) | Beli | 30.92 |
| RBC Capital | 18 Feb 2026 | 49.00 (43.91%) | Beli | 30.92 |
| 21 Jan 2026 | 45.00 (32.16%) | Beli | 36.01 | |
| Wedbush | 18 Feb 2026 | 52.00 (52.72%) | Beli | 30.92 |
| UBS | 07 Jan 2026 | 50.00 (46.84%) | Beli | 37.86 |
| Truist Securities | 06 Jan 2026 | 60.00 (76.21%) | Beli | 36.31 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| STEIN JEFFREY | 33.04 | - | 50,000 | 1,652,000 |
| Jumlah Keseluruhan Kuantiti Bersih | 50,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 1,652,000 | |||
| Purata Pembelian Keseluruhan ($) | 33.04 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| STEIN JEFFREY | Pengarah | 02 Mar 2026 | Beli (+) | 50,000 | 33.04 | 1,652,000 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events |
| 30 Jan 2026 | Pengumuman | IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 11 Jan 2026 | Pengumuman | IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Pengumuman | IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |